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Background: Extracellular vesicles (EVs) are thought to exert protective effects after ischemic and remote ische-
mic preconditioning. It is not well understood which EV content factors are most relevant for protective effects.
Wehypothesize that ischemic preconditioning leads to qualitative changes in EVmRNA content and quantitative
changes in EV size and number.
Methods: Using an in vivo porcine ischemic preconditioning model, EVs were collected from coronary venous
blood, and isolated by differential ultracentrifugations. The presence and purity of EV were veriﬁed by electron
microscopy and Western blot, and EV number was assessed by nanoparticle tracking analysis. The mRNA EV
was identiﬁed by microarray.
Results:Gene ontology analysis showedenrichment of EVmRNAcoding for proteins associatedwith regulation of
transcription, translation, extracellular matrix, morphogenic development and feeding behavior. There were
11,678 different mRNA transcripts detected in EV, where a total of 1103was signiﬁcantly increased or decreased
after preconditioning, ofwhich 638mRNA sequenceswere up-regulated and/or emerged due to preconditioning.
Several of themhave known associationwith ischemic preconditioning. Therewas no signiﬁcant difference in EV
quantity or size before and after preconditioning.
Conclusions: These ﬁndings demonstrate in an in vivomodel thatmyocardial ischemic preconditioning inﬂuences
the composition of mRNA in EV, including gene transcripts for proteins associated with the protective effect of
ischemic preconditioning. The ﬁnding that preconditioned parental cells release EV containing mRNA that is
qualitatively different from those released by non-preconditioned cells shows the importance of the external
milieu on parental cell EV production.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Extracellular vesicles (EVs) are present in all body ﬂuids, and they
are known to transport different types of cell contents, including
proteins, DNA and RNA [1–3]. Their biological function is currently not
completely understood. The term EV includes different secreted
membrane-enclosed vesicles such as exosomes andmicrovesicles, how-
ever there are no speciﬁc markers that distinguish subsets of EV from
one the other [4]. Most cell types, including cardiomyocytes, activelyability and freedom from bias of
reMedicine, University Hospital
ax: +46 90 131388.
nd Ltd. This is an open access article unsecrete EV through exocytosis by fusion of multi-vesicular bodies with
the plasma membrane or through budding from the cell membrane
[5–7].
Although the functions of EVs are not well understood, they contain
markers of conditions of the parent cell. EV from hypoxic cells contain
different proteins compared to EV from the same cells before hypoxia
[8,9]. When parent cells were exposed to different growth factors, a
change in EV messengerRNA (mRNA) composition has been demon-
strated [10]. The EV mRNA is presumed to have a functional impact if
transferred to a recipient cell, by itself leading to protein synthesis
[3,11]. Hence, EV contents can be conveyed to other cells and therefore
may be an important signaling mechanism between cells, which can
function to confer effects from remote parent cells.
While prolongedmyocardial ischemia can lead to permanent injury,
there are adaptive protectivemechanisms to provide extra resistance toder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of cardiac tissue where repetitive short exposures to ischemia followed
by reperfusion leads to increased cell tolerance for ischemia at a later
exposure. This is presumed to be brought about by internal cell mecha-
nisms activated by the short ischemic periods [12,13]. The mechanisms
of cellular protections from IPC are not fully known. Recently, EVs were
suggested as possible key mediators of protective effects. Extracellular
vesicles from the limb muscle and mesenchymal cells exposed to IPC
as well as coronary perfusate with EV from IPC hearts, have both
in vitro and in vivo, been associated with possible anti-apoptotic effects,
limited infarction size and improving cardiac function [14–16]. Another
recent publication has shown both how IPC related changes in EV con-
centration can occur, as well as the occurrence of EV related proteins
that can activate protein kinases already recognized in connection
with cardioprotective IPC effects [17]. Findings have also demonstrated
that cardiac progenitor cells might stimulate regeneration, and this
could lead to functional improvement in the injured myocardium due
to EV mediating cardioprotection [18,19].
The speciﬁc hypothesis of this study is that IPC leads to qualitative
changes in EV mRNA content and quantitative changes in EV size and
number. We aimed to study this in EV material collected in vivo in a
large animal model through using localized sampling and collection
coordinated with a distinct IPC treatment.
2. Materials and methods
Ethical approval for this study (dnr: A182-12) was obtained from
the Regional Animal Research Ethics Committee in Umeå, Sweden,
and was carried out in accordance with the Guide for the Care and Use
of Laboratory Animals (1996, National Academy of Science Institute
for Laboratory Animal Research, USA) and the EU Directive 2010/63/
EU for animal experiments (http://ec.europa.eu/environment/
chemicals/lab_animals/legislation_en.htm). The studymaterialwas col-
lected from anesthetized and surgically prepared domestic land-race
pigs.
2.1. Preparation
Animals were premedicated with ketamine 10 mg·kg−1 (Ketalar,
Pﬁzer,Morris Plains, New Jersey, USA) and xylazine 2mg·kg−1 (Rompun
vet, Bayer AB, Lyngby, Denmark) intramuscularly, and then an ear vein
intravenous cannulawas used for induction of anesthesiawith pentobar-
bital 10 mg·kg−1 (Pentobarbitalnatrium, Apoteksbolaget, Stockholm,
Sweden). Throughout the experiment anesthesia was maintained with
a continuous infusion of pentobarbital 5 mg·kg−1·h−1, fentanyl
20 μg·kg−1·h−1 (Fentanyl, Braun,Melsungen, Germany) andmidazolam
0.3mg·kg−1·h−1 (Dormicum, Roche, Basel, Switzerland). Nomuscle re-
laxants were used. Volume-controlled ventilation was used (Evita 4,
Dräger, Kiel, Germany) with a mixture of 30% oxygen and adjusted to
normocapnia by end-tidal capnometry. Intravenous Ringer's acetate
was infused at 15 mL·kg−1·h−1 throughout the protocol. Rectally
measured body temperaturewasmaintained at 38–39 °C by cloth covers.
At the end of the experiment the animalswere euthanized by 40mmol of
potassium chloride after a bolus of pentobarbital (around 200 mg).
Throughout the experiment the heart rate, mean arterial pressure
(MAP), ECG and central venous pressure (CVP) were recorded continu-
ously, with all data saved in digital format using a computer based
multi-channel acquisition and analysis system (AcqKnowledge, Biopac,
California, USA). In dorsal position, a tracheostomy was performed and
by surgical dissection neck artery and veins were exposed for cannula-
tion. A triple-lumen central vein catheter (Arrow-Howe Multi-Lumen
Central Venous Catheter, Vingmed, Järfälla, Sweden) was inserted for
CVP measurements and infusion of drugs and ﬂuids. For invasive
blood pressure an arterial catheter was placed in the carotid artery.
For selective blood sampling of the blood from coronary veins draining
the myocardial ischemic area, a coronary sinus catheter (CCS-7U-90A;Webster Labs, Altadena, California, USA) was placed with the tip
optimally positioned using ﬂuoroscopic guidance.
Midline sternotomy and pericardiotomy were performed, followed
by placing a patched snare for intermittent occlusion of the middle
portion of the left anterior descending artery (LAD), without injury to
the corresponding vein. Myocardial ischemia and accurate reperfusion
sampling was conﬁrmed by more than doubling of coronary lactate
production (Radiometer ABL-5, Copenhagen Denmark).
2.2. Myocardial ischemic preconditioning
The pigs were allowed to rest for 1 h after the surgical preparation
before baseline coronary venous samples were collected. Myocardial
IPC was created by temporary snare-occlusion for 10 min followed
by reperfusion during 20 min, repeated four times [20]. Coronary
venous samples (10 mL each) were collected every second minute
during a 20 min period, starting 20 min after last LAD snare release.
All blood samples were immediately centrifuged for 10 min (at 4 °C
and 1800 ×g) to separate the plasma, which was further mixed
with an equal amount of phosphate-buffered saline (PBS). Thereafter
samples were stored in −80 °C until EV isolation could be
completed.
2.3. Extracellular vesicle isolation
Extracellular vesicles were isolated by differential centrifugations
and preparative ultracentrifugation. Plasma samples were thawed in
room temperature and centrifuged for 30 min at 4 °C and 3000 ×g,
followed by 10,000 ×g for 35 min at 4 °C to remove cellular debris.
Supernatants were ultracentrifuged to separate the medium and the
EV pellets. All ultracentrifugation steps were conducted at 110,000 ×g
for 2 h and 4 °C using a L-90 Beckman centrifuge and the SW-41 rotor
(Beckman Instruments, Inc., Fullerton, CA). Pellets were resuspended
in PBS to a total volume of 1.5 mL followed by nuclease treatment
(Benzonase Nuclease Ultrapure, ≥250 units/μL, Sigma-Aldrich, Brøndby,
Denmark), for 1 h at 37 °C and 80 rpm (for removal of possible extracel-
lular RNA and DNA). Next, samples were added to the top of a sucrose
gradient (prepared by equal amounts of 20% and 40% sucrose solution),
followed by immediate ultracentrifugation. Extracellular vesicle frac-
tions were collected by taking 2–3 mL of solution from gradient zone,
which were further washed with PBS and once again ultracentrifuged.
The pellet was resuspended in PBS before storage in−80 °C.
2.4. Evaluation of extracellular vesicle preparation
Electronmicroscopy (EM) andWestern blot (described below)were
performed as a quality control step to conﬁrm the presence of EV aswell
as the absence of contaminants such as larger vesicles and cells. Electron
microscopy of isolated EV was performed at the electron microscopy
unit Emil, Clinical research center, Huddinge, Sweden. Nanoparticle
tracking analysis (NTA) (NanoSight N300, Malvern Instruments Ltd.
Malvern, United Kingdom) was used for quantiﬁcation and sizing of
EV for isolates from four pigs, before and after IPC, with ﬁnal samples
diluted in PBS (1:500–1:1000).
A Western blot analysis was performed on lysed EV. CD81 was used
as an EV marker and GRP78 to detect potential contamination of cells
and apoptotic bodies, and these were compared to crushed porcine
myocardial tissue in a cell suspension. Although, this procedure is
intended to quantify several proteins in the EV preparation, the limited
amount available porcine antibodies restricted us of using only CD81
and GRP78 [4]. Protein concentration was determined using BCA
Protein assay (Pierce) and samples of 5–10 μg protein were separated
by 10% and 5–14%Mini-PROTEANTGX gels (Bio-Rad, USA). The separat-
ed protein fractions in the gels were then transferred to PVDF
membranes (Midi format 0.2 μm, Bio-Rad, USA) using Trans-Blot
Turbo (Transfer System, Bio-Rad, USA). The membranes were blocked
Fig. 1.Western blot results. CD81 is present in extracellular vesicle (EV) (labeled Vesicles
in the ﬁgure) samples and GRP78 in cell suspension (labeled Cells in the ﬁgure). The ab-
sence of CD81 in cell suspension and GRP78 in EV identiﬁes isolated vesicles as EV with
no detectable contamination of apoptotic bodies.
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at 21 °C, washed with PBS Tween (PBST) and subsequently incubated
with an anti-CD81 antibody (Santa Cruz Biotechnology, Texas, USA),
diluted 1:200 in 1% PBST and anti GRP-78 antibody (Abcam,UK), and di-
luted 1:1000 in 1% PBST at 4 °C overnight. Themembraneswerewashed
with PBST before they were incubated with secondary goat anti-rabbit
antibody (IRDye, 800 CW, LI-COR, USA) and diluted 1:10,000 in 1%
PBST for 1 h at 21 °C. After washing with PBST the proteins were
visualized using LI-COR ODYSSEY GLx.
2.5. Extracellular vesicle DNA/RNA preparation
The Qiagen Allprep DNA/RNA Mini kit (Qiagen, Alameda, CA, USA)
was used to isolate DNA and mRNA from the EV preparation, according
to the manufacturer's instructions. DNA and mRNA were stored at
−80 °C and the DNA was kept for potential later analysis. mRNA con-
tent of the EV pellet was quantiﬁed using a nanodrop spectrophotome-
ter (nanoDrop Technologies Inc., Wilmington, Delaware, USA).
2.6. Microarray expression analysis
RNA quality was evaluated using the Agilent 2100 Bioanalyzer sys-
tem (Agilent Technologies Inc., Palo Alto, CA, USA). Fifty nanograms of
total RNA from each sample was used to generate ampliﬁed and bio-
tinylated sense-strand cDNA from the entire expressed genome accord-
ing to the GeneChip® WT PLUS Reagent Kit User Manual (P/N 703174
Rev. 1, Affymetrix Inc., Santa Clara, CA, USA). GeneChip® ST Arrays
(GeneChip® Porcine Gene 1.0 ST Array) were hybridized for 16 h in a
45 °C incubator, rotated at 60 rpm. According to the GeneChip® Expres-
sion Wash, Stain and Scan Manual (P/N 702731 Rev. 3, Affymetrix Inc.,
Santa Clara, CA, USA) the arrays were then washed and stained using
the Fluidics Station 450 and ﬁnally scanned using the GeneChip®
Scanner 3000 7G.
2.7. Microarray data
The raw data was normalized in the free software Expression
Console provided by Affymetrix (http://www.affymetrix.com) using
the robust multi-array average (RMA) method ﬁrst suggested by Li
and Wong in 2001 [21,22]. Subsequent analysis of the gene expression
data was carried out in the freely available statistical computing lan-
guage R (http://www.r-project.org) using packages available from the
Bioconductor project (www.bioconductor.org). In order to search for
the differentially expressed genes before and after IPC an empirical
Bayes moderated t-test was then applied, using the robust version of
the lmFit function, from the ‘limma’ package [23,24]. To address the
problemwith multiple testing, p-values were adjusted using the meth-
od of Benjamini and Hochberg [25].
2.8. Ortholog analysis
Since the functions of many Sus scrofa genes are not well known, we
chose to identify orthologous genes in the better studied Homo sapiens.
Accession numbers for highly expressed genes in the EV of Sus Scrofa,
were translated to the corresponding UniProt ID, using the ID mapping
tool at www.uniprot.org. The UniProt IDs could further be used to
identify human orthologs in the list obtained from InParanoid8
(http://inparanoid.sbc.su.se/cgi-bin/e.cgi) [26].
2.9. Gene ontology
Gene ontology analysis was performed on the 2000 human genes
whose orthologs showed the highest expression in all samples, using
the functional annotation clustering tool in theweb-accessible program
DAVID Bioinformatics version 6.7 (http://david.abcc.ncifcrf.gov/home.jsp). Clusters having enrichment score N 1.3 were regarded
as signiﬁcant [27].
2.10. Analysis of gene expression data from microarray
Average expression of each genewas calculated as themean value of
samples before IPC (n = 5) and the mean of the reperfusion samples
(n=4, onewas excluded from this analysis due to the lack of material).
To adjust for non-speciﬁc hybridization the limit of expression was set
as above the background signal (N1.5). Only these genes were further
analyzed. Stating this, an average signal below 1.5 was considered not
existing. Therefore, samples before IPC, with average expression b1.5
increasing to N1.5 during reperfusionwere considered to have emerged
as a result of IPC. Vice versa, samples expressed N1.5 before IPC and de-
clined to b1.5 after reperfusion were considered to have disappeared
due to IPC. When average expression was N1.5 during baseline and re-
perfusion, signiﬁcant up- or downregulated genes were deﬁned as log
2 Fold Change (log 2 FC) ± 0.5. Statistical signiﬁcance was stated as
P b 0.05. The gene expression log 2 FC was calculated as the mean
value of reperfusion relative to the mean value before IPC.
3. Results
Five animals were included and completed the protocol for EV
sampling before IPC and during reperfusion. The average animal weight
was 39.6 ± 4.2 kg (standard deviation). Hemodynamic measurements
(all n = 5) before and after (respectively) ischemic preconditioning
were as follows: heart rate 89 ± 22 and 82 ± 8.0 beats per minute,
mean arterial pressure 92 ± 10.1 and 77 ± 15.7 mm Hg, and central
venous pressure 3 ± 0.7 and 4 ± 2.0 mm Hg.
3.1. Purity of EV preparation and EV characterization
To conﬁrm the presence of EV and estimate the purity of isolation,
the EV fractions were evaluated by Western blot, EM and NTA. CD81, a
known EV marker, was found in EV samples but not in the porcine cell
suspensionwhich indicates that EV preparationswere correctly puriﬁed
(Fig. 1). An endoplasmic reticulum protein, GRP78, was detected in the
cell suspension but not in EV; indicating the absence of contaminating
apoptotic bodies in the EV preparation (Fig. 1). EM analysis of the EV
fractions demonstrated typical morphology of EV and no cell debris
(Fig. 2). Nanoparticle tracking analysis showed EV ranging from 30 to
350 nm, the major part between 75 and 200 nm (data not shown).
There was no signiﬁcant difference in plasma EV quantity before and
after IPC (data not shown).
3.2. Microarray
According to settings for expression signal and log 2 FC, microarray
assessment detected 11,678 different mRNA transcripts in cardiac EV
Fig. 2. Electron microscopy picture of isolated extracellular vesicle. Note the ‘cup-shaped’
appearance.
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enrichment of mRNA coding for proteins associated with regulation of
transcription, translation, extracellular matrix, morphogenic develop-
ment and feeding behavior. A total of 1103 (9.5%) among the detected
11,678 gene transcripts were signiﬁcantly increased or decreased after
IPC (see Supplemental Table). Also, 638/1103 (57.8%) of themRNA tran-
scripts were up-regulated, where 634 did not exist before IPC but
emerged during reperfusion. There were 465/1103 (42.2%) mRNA
sequences that were down-regulated, where 456 existed before IPC
but disappeared during reperfusion (Fig. 3). As all porcine genes are
not annotated today, biological function of 30% of the induced gene
transcripts by IPC (638) could not be assessed.
In this in vivo study we aimed to evaluate whether IPC inﬂuenced
cardiac EV mRNA content and whether genes with a recognized associ-
ation to cardioprotectionwere upregulated. Among 638 transcripts that
appeared or increased, the mRNA sequence of transcription factors
signal transducer and activator of transcription-3 (STAT3) and T-cell
transcription factors/lymphoid-enhancer binding factor (TCF/LEF), the
enzymes cyclooxygenase-2 (COX-2) and glycogen synthase kinase 3
beta (GSK-3β), and the receptor ryanodine receptor type 2 (RyR-2)
were detected (Table 1). All these have been, by different pathways,Fig. 3. Number of distinct mRNA transcripts in extracellular vesicles before ischemic pre-
conditioning (IPC) and after. Both downregulation and upregulation of gene transcription
were observed after IPC.demonstrated to be cardioprotective during I/R and/or IPC [28–33].
The gene transcript of hypoxia-inducible factor 1 alfa (HIF-1α) was not
found [34].
4. Discussion
The main ﬁndings are that the mRNA contents in EVs changed after
myocardial IPC in vivo. To our knowledge, this is the ﬁrst demonstration
of an alteration of EV mRNA content related to preconditioning in vivo.
The fact that the preconditioned parental cells release EV containing
mRNA that is qualitatively different from those released by non-
preconditioned cells, not only shows the importance of the external mi-
lieu of parental cells, but also strongly indicates that the EV contents of
mRNA are biologically relevant. While these EVs were harvested from
coronary venous efﬂuent, there is no direct identiﬁcation of the parent
cells for these EVs. Hence these vesicles may derive from cardio-
myocytes, ﬁbroblasts or endothelial cells, even though the sampling
was highly localized. Still, in this design we can assume that EVs con-
taining gene transcripts that changed after myocardial IPC originate
from the heart, and that transcription of approximately 1000 mRNA
sequences was affected by IPC.
Gene ontology analysis, on the 2000 genes with highest expression,
showed an enrichment of mRNA coding for proteins associated with
regulation of transcription, translation, extracellular matrix, morpho-
genic development and feeding behavior. This is consistent with the
enrichment of ribosomal mRNA that we identiﬁed in EV/exosomes/
cardiosomes from cultured cardiomyocytes [10]. These ﬁndings suggest
that the EV content at least partly is destined for supporting target cells
and their protein synthesis and cellular remodeling. Several of the iden-
tiﬁedmRNA sequences that emerged due to IPC are from previous stud-
ies known to have associations to cardioprotective phenomena. Five
mRNAs translate cell proteins with strong association to IPC: STAT3,
TCF/LEF, COX-2, GSK-3β and RyR2. The cardioprotective effects by IPC
are associated with two phases, one early phase lasting for about 2 h
after IPC, followed by a later phase starting some hours later and lasting
for a couple of days [13]. Protective signals of EV mRNAmay contribute
more to the later phase of cardioprotection, although it is still possible
that some aspects of the early phase are mediated in part by EV
mRNA. The transcription factors STAT3 and TCF/LEF have each revealed
to be cardioprotective. Activation of STAT3 has demonstrated
cardioprotection by improvedmitochondrial function and upregulation
of anti-apoptotic proteins [29,31]. TCF/LEF is known to protect themyo-
cardium during IPC by regulating genes important for anti-apoptosis
and angiogenesis [32]. In addition, these transcription factors have in
common to initiate the expression of COX-2; an enzyme recognized to
become induced by IPC and mediate cardioprotection [35,36,37,38].
Myocardial tissue levels of COX-2 mRNA have been shown to increase
at 1 h after IPC and COX-2 protein and its speciﬁc cardioprotective pros-
tanoid metabolites (PGE2 and PGI2) at 24 h after IPC [27,36,37,38]. In
concordance with a previous study where it was shown that EV/
prostasomes contain ribosomes [39], it is suggested that IPC increases
the expression of TCF/LEF and STAT3 in the cardiac EVs, ﬁrstly to obtain
their direct cardioprotective effects and secondly, to guarantee further
COX-2 protein synthesis in recipient cells. In addition,mRNA transcripts
of COX-2were induced in cardiac EVs after IPC,whichmay demonstrate
an alternative pathway to obtain the cardioprotective mechanisms of
COX-2 in target cells. These two ways of transferring an increase of
COX-2 effect in recipient cells could indicate that the COX-2 effect of
IPC is transferred by EV.
It is well recognized that HIF-1α is induced under hypoxic condi-
tions, but still it was not detected in our cardiac EVs. HIF-1α has been
suggested necessary for cardioprotection in IPC and induces expression
of various cardioprotective genes such as COX-2 [40,41] consistent with
the present results.
EvenmRNA of GSK-3β, an enzyme being important in cardiomyocyte
apoptosis, was increased due to IPC. The enzyme in its phosphorylated
Table 1
Speciﬁc gene sequences induced by ischemic preconditioning and associated with cardioprotection.
Gene symbol UniProtID Average expression before IPC Average expression after IPC Gene description
STAT3 E7CR02 Q19550 Not detected 1.72 Signal transducer and activator of transcription 3
TCF/LEF B3GQS6 Not detected 1.66 Lymphoid enhancer-binding factor 1
RYR2 NA Not detected 1.52 Ryanodine receptor 2 (cardiac)
GSK3B F1SPD2 Not detected 1.51 Glycogen synthase kinase 3 beta
COX2 Q69GF7 Not detected 1.8 Cytochrome c oxidase subunit II
IPC = ischemic preconditioning.
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inhibiting opening of mitochondrial permeability transition pores [30].
The amount of RyR2 mRNA (a well recognized myocardial Ca2+ channel
receptor) increased in cardiac EVs after IPC. Cytosolic Ca2+ overload is
one important pathophysiological mechanism of myocardial damage
during ischemia/reperfusion (I/R), and IPC improves Ca2+ homeostasis
during reperfusion [42]. Studies have presented Ca2+ overload to be
caused by defect Ca2+ release through ischemically impaired RyR2. It
has been suggested that pharmacological modulation restoring and
preventing RyR2 dysfunctionmay be cardioprotective duringmyocardial
I/R, explaining at least some of the infarct sparing effects of IPC [33,43,44].
This study was conﬁned to explore cardiac EV mRNA. We can
therefore only presume that altered gene transcripts will further re-
sult in a biological function of a translated protein. In this explorative
study, microRNA, DNA, and protein content in recipient cells were
not investigated. We and others have previously shown in vitro
that the transferred EV mRNA was functional by inducing gene ex-
pression changes and becoming translated to proteins in the target
cell [3,11]. The co-existence of miR, mRNA and DNA fragments in
EV, and the observation that they are all qualitatively changed by
the external milieu, support the idea of a hierarchically organized
signal system exerting protective actions on recipient cells.
MicroRNA appears as the fastest signal from parental cells, followed
bymRNA, which has amore sustained biological signal, and also DNA
fragment signals.
Concerning limitations of the study design, gene function of the por-
cine genome is less known and few antibodies are available for more
speciﬁc functional studies. Still, a large animal model is needed for
collecting enough EVs, and is more suitable for conclusions concerning
the human situation. In future studies, unique identiﬁers on EV, repre-
sentative of the parent cells, will facilitate more speciﬁc analysis of EV
contents in in vivo models. Mechanisms of EV packaging needs to be
better understood aswell as the time relationship of stimulus and EV re-
lease from parent cells. In this study, EVs were collected subsequent to
the ischemic stimulus, since it is well established that IPC has induced
cardiac protection by then. However, it is possible that EV production
and EV contents change over time after the stimulus, which is the rea-
son why it would be relevant to study the signal of cardioprotection
over time.
In summary, these ﬁndings demonstrate for the ﬁrst time in an
in vivo model that IPC in the heart muscle inﬂuences the composition
of mRNA in EVs harvested from the coronary venous blood. We also
show that EVs from cardiac cells exposed to IPC contain gene transcripts
for proteins which are associated with cardioprotective effects of IPC.
Hence, EVs contain transcription material, which we suggest is relevant
for the protective effects of IPC in the heart muscle.
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